FDA Lays Out Rules For Early Study Of Higher-Risk Devices

Law360, New York (October 2, 2013, 2:56 PM EDT) -- The U.S. Food and Drug Administration on Tuesday laid out new expectations for early clinical studies of higher-risk medical devices, describing a litany of conditions manufacturers must meet before such analyses are performed.

The 40-page guidance document covers investigational device exemptions that allow trials of unapproved products and applies only to so-called early feasibility studies, which tend to occur before device design has been finalized and involve a small group of 10 or fewer human subjects.

While many of the rules surrounding IDEs are contained in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.